<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1356">
  <stage>Registered</stage>
  <submitdate>21/04/2005</submitdate>
  <approvaldate>21/04/2005</approvaldate>
  <actrnumber>ACTRN12606000270516</actrnumber>
  <trial_identification>
    <studytitle>High blood sugar levels and insulin treatment in preterm babies. The HINT trial.</studytitle>
    <scientifictitle>Randomised controlled trial on the effect of tight glycaemic control with insulin in hyperglycaemic very low birth weight (VLBW) preterm neonates on growth.</scientifictitle>
    <utrn />
    <trialacronym>HINT trial</trialacronym>
    <secondaryid>Perinatal Trials Registry: PTR544</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neonatal Hyperglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Continuous intravenous insulin infusion starting at 0.05 units/kg.hour, titrated to maintain target blood glucose levels. In the intervention group insulin will be started in hyperglycaemic babies after two concecutive blood glucose levels of &gt; 8.5 mmol/l, 4 hours apart. The insulin will be titrated to maintain the blood glucose level from 4-6 mmol/l. </interventions>
    <comparator>n the control group insulin will only be started in hyperglycaemic babies who are over 3 days old, and have persistently elevated blood gluocose levels &gt; 10 mmol/l, and unable to tolerate 100 cal/kg.day. Once insuin is started the dose will be titrated to maintain the blood glucose level 8-10 mmol/l. The trial will continue until 36 weeks post menstrual age.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lower leg growth rate</outcome>
      <timepoint>Twice a week until 36 weeks post menstrual age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Number of episodes of sepsis</outcome>
      <timepoint>Until 36 weeks post menstrual age.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Need for and number of blood transfusions</outcome>
      <timepoint>Until 36 weeks post menstrual age.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Myocardial hypertrophy</outcome>
      <timepoint>At randomisation, 2 and 4 weeks post randomisation and 36 weeks post menstrual age.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Cortisol level at randomisation and  insulin like growth factor - 1 (IGF-1) + insulin levels.</outcome>
      <timepoint>At randomisation, 7 and 14 days post randomisation and 36 weeks post menstrual age.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Incidence of hypoglycaemia (blood glucose level &lt; 2.6 mmol/l)</outcome>
      <timepoint>Until 36 weeks post menstrual age.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Babies &lt;30 weeks gestation or &lt;1500g and 2 consecutive blood glucose measurements of &gt;8.5 mmol/l, 4 hours apart.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hyperglycemia secondary to an accidental overdose.  Babies with major congenital malformation. Imminent death</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Stratified allocation, by gender and birth weight for gestational age ( &gt; or &lt; 10 th centile)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>18/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>88</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Jane Alsweiler</primarysponsorname>
    <primarysponsoraddress>Newborn Services, Level 9, Support Building, Auckland City Hospital, Private Bag 92024, Auckland 1023, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>PO Box 110 139
Auckland Hospital
Auckland 1148,
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Starship Foundation</fundingname>
      <fundingaddress>Park Road
Grafton 
Auckland 1023
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Paykel Trust</fundingname>
      <fundingaddress>PO Box 37 760 Parnell 
Auckland 1151, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Frank Bloomfield,</sponsorname>
      <sponsoraddress>Newborn Services, Level 9, Support Building, Auckland City Hospital, Private Bag 92024, Auckland, New Zealand</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Jane Harding</sponsorname>
      <sponsoraddress>Vice Chancellors Office, Old Government House, Symond St,
University of Auckland, Private Bag 92019, Auckland</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Many very preterm and small babies develop high blood sugar levels in the first few days to weeks after birth. Recent studies in critically ill adults with high blood sugar levels have shown that treatment with insulin to keep blood sugar levels in the normal range improved survival and reduced complications, regardless of whether the patients were diabetic or not. However, we do not know if the same is true for preterm babies. The purpose of this study is therefore to find out if babies with high blood sugar levels do better if their blood sugar level is kept in the normal range (4-6 mmol/l) with insulin treatment compared with the current practice of aiming for a blood sugar level less than 10 mmol/l. This study is a pilot study to determine if treatment is feasible in the newborn and improves growth.  If successful, this would lead to a multi centre trial to determine if this treatment decreases mortality or improves neurodevelopmental outcome at 2 years of age.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland City Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>NTX/05/06/054</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jane Alsweiler</name>
      <address>Newborn Services
Level 9, Support Building
Auckland City Hospital
Park Road 
Grafton
Auckland</address>
      <phone>+64 9 3797440 ext 25365</phone>
      <fax>+64 9 3072804</fax>
      <email>jalsweiler@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jane Alsweiler</name>
      <address>Newborn Services
Level 9
Support Building
Auckland City Hospital
Park Road 
Grafton Auckland</address>
      <phone>+64 9 3797440 ext 25365</phone>
      <fax>+64 9 3072804</fax>
      <email>jalsweiler@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>